Nicholas G Zaorsky1, Charles T Lee2, Eddie Zhang2, Thomas J Galloway2. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA; Department of Radiation Oncology, Penn State Cancer Institute, Hershey, USA. Electronic address: nicholaszaorsky@gmail.com. 2. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Abstract
BACKGROUND AND PURPOSE: To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin. MATERIALS AND METHODS: Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as "good," "fair," or "poor." The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED3) and cosmetic outcomes. RESULTS: A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 years, median follow-up was 36 months, and median dose was 45 Gy/10 fractions at 4.4 Gy/fraction. At BED3 of 100 Gy, "good" cosmesis was more frequently observed in patients receiving BT, 95% (95% CI: 88-100%) vs 79% (95% CI: 60-82%), p < 0.05. Similar results were found for "good" cosmesis at BED3 >100 Gy. No difference in "poor" cosmesis was noted at any BED3. LR was <7% for both at one year. CONCLUSION: BT has favorable cosmesis over EBRT for skin SCCs/BCCs at common fractionation regimens. Prospective studies comparing EBRT vs BT are warranted.
BACKGROUND AND PURPOSE: To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin. MATERIALS AND METHODS: Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as "good," "fair," or "poor." The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED3) and cosmetic outcomes. RESULTS: A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 years, median follow-up was 36 months, and median dose was 45 Gy/10 fractions at 4.4 Gy/fraction. At BED3 of 100 Gy, "good" cosmesis was more frequently observed in patients receiving BT, 95% (95% CI: 88-100%) vs 79% (95% CI: 60-82%), p < 0.05. Similar results were found for "good" cosmesis at BED3 >100 Gy. No difference in "poor" cosmesis was noted at any BED3. LR was <7% for both at one year. CONCLUSION: BT has favorable cosmesis over EBRT for skin SCCs/BCCs at common fractionation regimens. Prospective studies comparing EBRT vs BT are warranted.
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: Chante Karimkhani; Robert P Dellavalle; Luc E Coffeng; Carsten Flohr; Roderick J Hay; Sinéad M Langan; Elaine O Nsoesie; Alize J Ferrari; Holly E Erskine; Jonathan I Silverberg; Theo Vos; Mohsen Naghavi Journal: JAMA Dermatol Date: 2017-05-01 Impact factor: 10.282
Authors: Alejandro Tormo; Francisco Celada; Silvia Rodriguez; Rafael Botella; Antonio Ballesta; Michael Kasper; Zoubir Ouhib; Manuel Santos; Jose Perez-Calatayud Journal: J Contemp Brachytherapy Date: 2014-06-03
Authors: Vladimir Avkshtol; Yanqun Dong; Shelly B Hayes; Mark A Hallman; Robert A Price; Mark L Sobczak; Eric M Horwitz; Nicholas G Zaorsky Journal: Res Rep Urol Date: 2016-08-18
Authors: Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet Journal: Front Med (Lausanne) Date: 2022-06-27
Authors: Grzegorz Bielęda; Adam Chicheł; Marek Boehlke; Grzegorz Zwierzchowski; Artur Chyrek; Wojciech Burchardt; Patrycja Stefaniak; Natalia Wiśniewska; Kinga Czereba; Julian Malicki Journal: J Contemp Brachytherapy Date: 2022-03-25
Authors: Łukasz Raszewski; Artur J Chyrek; Magdalena Marciniak; Wojciech M Burchardt; Grzegorz M Biele da; Adam Chicheł Journal: J Contemp Brachytherapy Date: 2021-05-07